



LATVIJAS JURAS MEDICINAS CENTRS JSC

CONSOLIDATED INTERIM REPORT FOR THE 3 MONTHS OF 2013

PREPARED IN ACCORDANCE WITH INTERNATIONAL FINANCIAL REPORTING STANDARDS

(Translation of the Latvian original)

Original of consolidated financial report in LVL expressed in EUR. Exchange rate 0,702804 EUR/LVL.

LATVIJAS JURAS MEDICINAS CENTRS JSC
TABLE OF CONTENTS

	PAGE
INFORMATION ABOUT PARENT COMPANY	3
COUNCIL AND BOARD OF THE GROUP	4
MANAGEMENT REPORT	5 – 6
STATEMENT OF MANAGEMENT'S RESPONSIBILITIES	7
CONSOLIDATED FINANCIAL STATEMENTS	8 – 12
CONSOLIDATED STATEMENT OF FINANCIAL POSITION	8 – 9
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME	10
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY	11
CONSOLIDATED STATEMENT OF CASH FLOWS	12
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS	13 – 22

**LATVIJAS JURAS MEDICINAS CENTRS JSC
INFORMATION ABOUT PARENT COMPANY**

COMPANY NAME: LATVIJAS JURAS MEDICINAS CENTRS JSC

LEGAL STATUS: Joint stock company

REGISTRATION: Registered in Latvian Register of Enterprises at 27.08.2004.
Registration Number: 40003306807

LEGAL ADDRESS: 23, Patversmes str., Riga, LV - 1005, Latvia

SHARES 800 000 public registered shares with face value 1,00 LVL
ISIN code:LV0000100741

MAJOR SHAREHOLDERS: Ilze Birka 17,50%
Martins Birks 17,50%
Ilze Aizsilniece 11,45%
Guna Shvarcberga 10,36%
Janis Birks 08,53%

REPORTING PERIOD: December 31, 2012 - March 31, 2013

AUDITORS NAME AND ADDRESS: System audit Ltd.
Licence No.53
Matisa str. 19-6
Riga, LV-1001
Latvia

LATVIJAS JURAS MEDICINAS CENTRS JSC
COUNCIL AND BOARD OF THE GROUP

Council of the Group Number of
shares owned at
31.03.2013

From April 28, 2010 till the consolidated financial statements signing day

Position	Name	
Chairman of the Council	Martins Birks	140 000
Member of the Council	Viesturs Shilins	3 038
Member of the Council	Ineta Gadzjus	-
Member of the Council	Jevgenijs Kalejs	5 283
Member of the Council	Uldis Osis	-

Board of the Group

From August 18, 2009 till the consolidated financial statements signing day

Position	Name	
Chairman of the Board	Janis Birks	68 215
Member of the Board	Marta Aizsiliece	1 344
Member of the Board	Andris Vigants	700

MANAGEMENT REPORT

In accordance with the paragraph 1 of Section 4 of the law "On Consolidated Annual Accounts" the joint stock company is under an obligation to prepare the consolidated annual report.

The consolidated financial report contains information concerning the current financial situation and future development of parent company JSC "Latvijas Juras medicinas centrs" (hereinafter referred to as LJMC) and its subsidiary company "Juras medicina" Ltd. (hereinafter referred to as JM).

This not audited consolidated financial report is prepared in accordance with International Financial Reporting Standards (IFRS) adopted by the European Union and is based on business continuation principle. The financial statements were drawn up in Latvian lats (LVL) and euros (EUR). The applied currency exchange rate is EUR/LVL 0.702804.

The current financial condition of the Group of companies and its development

The share of the parent company constitutes the dominant part of the group's assets, turnover and profits.

The loss before taxes of LJMC was 198252 EUR

The loss before taxes of JM was 13130 EUR

Important events that affected results of the Group's activities in reporting period

Key developments in LJMC during the year 2013 is offering new medical service, improving the quality of existing services with the help of modern medical technology, new specialists and better patient service culture and increase of operational efficiency based on rational use of resources.

A contract was signed with the National Health Service on state-paid medical services at last year's level.

On March 2013 Joint-stock company Latvijas Jūras medicīnas centrs „Ziemeļu diagnostikas centrs” received a quality certificate ISO 9001:2008 in functional diagnostics and radiology from DVN Certification OY/AB, Finland. This certificate is valid till March 14, 2016. The work on the initiation of ISO quality standards in the other structural units continues.

We have developed a conception for more rational use of premises at Vecmīlgrāvis area to reduce utility costs.

Significant rise of utilities and electricity tariffs, as well as the prices of medicines, medical materials and tools in comparison with previous year, has a negative effect on Company's financial performance 2013th. The short-term negative impact on spending leaves the depreciation of large investments in the information technologies at 2012th.

Overall, the 2012th 3 months revenue plan is executed at 101%.The expenditure side is overrun by 27 403 LVL (3%): including 5000 LVL utilities exceeding. Planned mother company's losses before taxes were 128 260 LVL; actual losses before taxes are 139 332 LVL.

The parent company has given to its subsidiary company a loan of 9500 LVL for 1 year with interest rate 5.3% per year in order to complete the restructuring of real estate.

The share price at the 31.12.12. was LVL 1,90; 31.03.13 - LVL 1,70.

MANAGEMENT REPORT

Important Events after the Balance Sheet Date

LJMC JSC has won the tender for PSKUS patient medical care for one year.

The share price at the 28.05.13 was LVL 2,00.

Future Development of the Group

The Board is planning to develop ambulatory care and offer new, high-quality services for the diagnostic and medical treatment, including Patversmes street 23 area. The development of joint computerized information and accounting system will continue. That will provide precise details of the services rendered to patient; the medical information will be in a digital format, as well as perspective – integration into the e-health system. The Board is optimizing the company's organization coping with the ongoing changes in the health service structure and changing public procurement levels.

Risk Management

On a regular basis the significant risks are assessed, involving a wide range of specialists. Measures are taken to mitigate the potential impact on business activities. Constantly, the Group's future development scenarios are reviewed based on the underlying and predictable market changes.

On behalf of the Group:

Chairman of the Board
Janis Birks

Member of the Board
Marta Aizsilniece

Member of the Board
Andris Vigants

Riga, 29 May, 2013.

LATVIJAS JURAS MEDICINAS CENTRS JSC
STATEMENT OF MANAGEMENT'S RESPONSIBILITIES

Consolidated financial statements are prepared to the best of our knowledge, in accordance with International Financial Reporting Standards adopted by the European Union. These financial statements give a true and fair view of the financial position of the Group and of its financial performance for the period ended 31 March 2013 in all essential aspects. In preparing those financial statements, management:

- selected suitable accounting policies and then apply them consistently;
- made judgments and estimates that are reasonable and prudent;
- prepared the financial statements on the going concern basis to presume that the Group will continue in business.

The Management Board is responsible for keeping proper accounting records, which disclose with reasonable accuracy at any time to ensure that financial statements drawn up from them comply with International Financial Reporting Standards as adopted by EU. They are also responsible for safeguarding the assets of the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The management Board is also responsible for operation of the Company in compliance with the legislation of the Republic of Latvia.

Chairman of the Board

Janis Birks

Member of the Board

Marta Aizsilniece

Member of the Board

Andris Vigants

Riga, 29 May, 2013.

LATVIJAS JURAS MEDICINAS CENTRS JSC
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS OF 31 MARCH 2013 AND 31 DECEMBER 2012

ASSETS	March 31, 2013	December 31, 2012	Notes	March 31, 2012
	EUR	EUR		EUR
Long-term investments:				
Intangible assets:				
Other intangible (fixed) assets	28 284	21 675	2	18 957
Total intangible assets	28 284	21 675		18 957
Fixed assets				
Land and buildings	2 436 611	2 501 696		1 711 786
Technological equipment and machines	1 031 588	1 112 949		1 202 745
Other fixed assets and fixtures	53 393	53 890		63 942
Fixed assets add-ons (EU funds)	156 571	156 571		156 571
Unfinished construction	-	-		853 645
Advance payments for fixed assets	0	4 727		-
Total fixed assets	3 678 163	3 829 833	2	3 988 690
Long-term financial assets				
Investment in associates	192 532	192 532	3	203 367
Total financial assets:	192 532	192 532		203 367
Total long-term investments:	3 898 979	4 044 039		4 211 014
Current assets:				
Inventories				
Raw materials	79 477	97 676	4	87 111
Total Inventories	79 477	97 676		87 111
Debtors:				
Trade receivables	256 863	110 406	5	470 733
Other receivables	12 282	9 501	6	46 610
Deferred expenditure	2 193	3 960	7	2 052
Total debtors	271 337	123 867		519 395
Cash funds	828 507	1 031 632	8	709 561
Total current assets	1 179 322	1 253 174		1 316 067
TOTAL ASSETS	5 078 300,61	5 297 214		5 527 081

LATVIJAS JURAS MEDICINAS CENTRS JSC
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS OF 31 MARCH 2013 AND 31 DECEMBER 2012

	March 31, 2013	March 31, 2013	Notes	March 31, 2012
LIABILITIES	EUR	EUR		EUR
Equity capital:				
Share capital	1 138 297,45	1 138 297,45	9	1 138 297
Reserves:				
c) reserves provided by the Articles of Association	45 521,94	45 521,94		45 522
d) fixed asset's revaluation reserve	894 687,56	929 362,95	23	1 033 391
Retained earnings:				
a) brought forward from previous years	2 033 467,36	2 089 619,57		1 967 233
b) current year comprehensive income (loss)	(211 290,79)	(96 947,37)		(28 127)
Total shareholders' equity	3 900 683,52	4 105 854,54		4 156 315
Non-controlling interest	1 774,33	1 865,39		1 915
Total equity capital	3 902 457,85	4 107 719,93		4 158 230
Provisions for liabilities and charges:				
Provisions for vacations	69 252,59	69 252,59		119 792
Deferred tax provisions	144 979,25	151 097,60	22	152 268
Total provisions	214 231,84	220 350,19		272 059
Non-current liabilities:				
Deferred income	596 678,45	596 678,45	10	372 789
Total non-current liabilities	596 678,45	596 678,45		372 789
Current liabilities:				
Advance payments	5 782,55	18 269,67	11	197 041
Trade Payables	94 639,46	89 771,83	12	280 166
Taxes and social security payments	129 277,87	121 261,40	13	113 379
Other payables	135 232,58	143 162,25	14	133 416
Total current liabilities	364 932,46	372 465,15		724 001
Total liabilities	961 610,91	969 143,60		1 096 791
TOTAL EQUITY, PROVISIONS AND LIABILITIES	5 078 300,60	5 297 213,72		5 527 081
				-
CR	3,23	3,36		1,82
DR	0,19	0,18		0,13

LATVIJAS JURAS MEDICINAS CENTRS JSC
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE PERIODS ENDED 31 MARCH 2013 AND 31 DECEMBER 2012

	2013, 3 month period	2012, 12 month period	Notes	2012, 3 month period
	EUR	EUR		EUR
Net sales	1 252 016	5 391 741	15	1 316 405
Cost of goods sold	(1 373 848)	(5 135 134)	16	(1 267 174)
Gross profit or loss	(121 832)	256 606		49 231
Administrative expenses	(118 558)	(479 323)	17	(113 581)
Other operating income	42 101	149 830	18	37 027
Other operating expenses	(13 096)	(7 163)	19	(841)
Income from investment in associate	-	186	20	-
Interest income and similar income	3	38	21	20
Profit (loss) before taxes	(211 382)	(79 825)		(28 143)
Corporate income tax	-	(17 188)	22	-
NET PROFIT OR LOSS	(211 382)	(97 013)		(28 143)
Other comprehensive income				
Peļņa no asociētā uzņēmuma daļu iegādes	-	-		-
Other comprehensive income for the year, net of tax	-	-		-
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	(211 382)	(97 013)		(28 143)
Profit attributable to				
Owners of LJMC	(211 290,8)	(96 947)		(28 127)
Non-controlling interest	(91)	(65)		(16)
	(211 382)	(97 013)		(28 143)
Total comprehensive income attributable to				
Owners of LJMC	-	-		-
Non-controlling interest	-	-		-
	-	-		-
EBITDA	(33 425)	588 285		-
Number of shares	800 000	800 000		800 000
Earnings per Share (EPS)	(0,26)	(0,12)		(0,03)

LATVIJAS JURAS MEDICINAS CENTRS JSC
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE PERIODS ENDED 31 MARCH 2013 AND 31 DECEMBER 2012

	Share capital	Reserves provided by the Articles of Association	Properties revaluation reserve	Previous years retained earnings	Current year profit	Non-controlling interest	Total
	EUR	EUR	EUR	EUR	EUR	EUR	EUR
At 31 December 2011	1 138 297	45 522	1 068 067	2 043 196	(116 758)	1 931	4 180 255
Previous years retained earnings	-	-	-	(116 758)	116 758	-	-
Dividends paid	-	-	-	-	-	-	-
Depreciation of revaluation surplus	-	-	(163 182)	163 182	-	-	-
Deffered tax on revaluation surplus	-	-	24 478	-	-	-	24 478
Profit on purchase of shares from associates	-	-	-	-	-	-	-
Total comprehensive income for the year	-	-	-	-	(96 947)	(65)	(97 013)
At 31 December 2012	1 138 297	45 522	929 363	2 089 620	(96 947)	1 865	4 107 720
Previous years retained earnings	-	-	-	(96 947)	96 947	-	-
Depreciation of revaluation surplus	-	-	(40 795)	40 795	-	-	-
Deffered tax on revaluation surplus	-	-	6 120	-	-	-	6 120
Profit on purchase of shares from associates	-	-	-	-	-	-	-
Total comprehensive income for the year	-	-	-	-	(211 291)	(91)	(211 382)
At 31 March 2013	1 138 297	45 522	894 688	2 033 467	(211 291)	1 774	3 902 458

LATVIJAS JURAS MEDICINAS CENTRS JSC
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE PERIODS ENDED 31 MARCH 2013 AND 31 DECEMBER 2012

	2013, 3 month period EUR	2012, 12 month period EUR	NOTES	2012, 3 month period EUR
Cash flows from operating activities				
Net income before tax	(211 382)	(79 825)		(28 143)
Adjustments:				
a) depreciation of fixed assets	174 925	678 852	2	162 320
b) depreciation of intangibles	3 031	6 446	2	184
c) provisions	-	(50 539)		-
d) loss (gain) on sale of fixed assets	4	582		-
e) interest income	(3)	(38)	20	(20)
f) gain (loss) from investments in associates	-	(186)	19	(11 022)
2. Changes in operating current assets and liabilities	(33 425)	555 291		123 319
Corrections				
a) receivables	(147 471)	111 851		(267 440)
b) inventory	18 199	(2 150)		(1 881)
c) current liabilities	(7 521)	(378 350)		(23 768)
3. Gross operating cash flow	(170 218)	286 642		(169 770)
4. Paid interest	-	-		-
4. Paid corporate income tax	-	(5 080)	12	(3 048)
5. Net cash used in operating activities	(170 218)	281 562		(172 818)
II. Cash flow used in investment activities				
1. Purchase of shares of associates	-	-		-
2. Purchase of fixed assets	(32 910)	(701 282)	2	(333 514)
3. Income from sale of fixed assets	-	531		-
Saņemtās dividendes	-	11 022		-
4. Received interest	3	38	20	20
5. Net cash from investment activities	(32 907)	(689 692)		(333 494)
III. Cash flows used in financing activities				
1. Saņemti EU fondi	-	223 889		-
2. Settlement of loans	-	-		-
3. Paid dividends	-	-		-
2. Net cash from financing activities	0	223 889		-
IV. Net increase (decrease) in cash	(203 125)	(184 241)		(506 312)
V. Cash at the beginning of the period	1 031 632	1 215 872		1 215 872
VI. Cash at the end of the period	828 507	1 031 632		709 560

LATVIJAS JURAS MEDICINAS CENTRS JSC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIODS ENDED 31 MARCH 2013 AND 31 DECEMBER 2012

GENERAL INFORMATION

“Latvijas Juras Medicinas Centrs” is a joint-stock company (the Company) incorporated in the Republic of Latvia on 27 August 1996. The consolidated financial statements incorporate the financial statements of the Company and its subsidiary - "Juras medicina" Ltd. (the Group).

The Group's main activity is health care services.

1. ACCOUNTING PRINCIPLES

Basis of consolidation

The consolidated financial statements have been prepared in accordance with the International financial reporting standards adopted by the European Union. Enclosed financial statements are prepared in the national currency of Latvia, the lats (LVL).

There is no difference in the dates of the Statements of financial position of the Company and its subsidiary.

The interest of minority shareholders is stated at the minority proportion of the net assets.

All significant intercompany transactions and balances among Group companies are eliminated on consolidation.

The net assets' portion attributed to the parent company are offset with the investment and have been eliminated. The retained earnings portion attributed to the parent company are earned after the acquisition date of shares are included in the consolidated retained earnings.

Foreign currency

Transactions denominated in foreign currencies are converted into Lats by the official exchange rate of the Bank of Latvia at the date of transaction. Monetary assets and liabilities are converted by the exchange rate of the Bank of Latvia as on the date of statements of financial position.

The applicable rate used for the principal currencies were the follows:

	March 31, 2013	December 31, 2012
EUR	0.702804	0.702804
USD	0,531	0,547

Gain or loss on conversion is posted to the statement of comprehensive income on the official exchange rate of the Bank of Latvia as of the statement of financial position date and recognized in the period when they incurred.

Exchange differences arising on the settlement of monetary items are recognized in the period in which they arise.

Cash and cash equivalents

The statement on cash flows is prepared according to IAS 7.

LATVIJAS JURAS MEDICINAS CENTRS JSC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIODS ENDED 31 MARCH 2013 AND 31 DECEMBER 2012

Trade receivables

Trade receivables are stated at their net realizable value. Trade receivables represent the gross balance due from customers less provision, if any, for doubtful accounts receivable. Provision for doubtful accounts receivable at the balance sheet date represents the estimated amounts of probable losses that might have been incurred at the statement of financial position date based on individual evaluation of each debtor.

Inventory

Inventories are stated at the lower of cost or market, using FIFO method.

Fixed assets

Fixed assets excluding real estate are stated at historical cost, less accumulated depreciation. The cost of the item comprises its purchase price, including import duties and any directly attributable costs of bringing the asset to working condition for intended use. The cost of self-constructed asset is determined using the same principles as for an acquired asset. Only assets with its useful life more than one year are capitalized. Depreciation is calculated based on the historical cost.

Separate accounts are used for assets acquired by EU funding.

Repair and maintenance costs are expensed when incurred. Capital expenditures such as refurbishment of buildings and improvements to structural elements are recognized as an asset if the expenditures improve the condition of the asset beyond its original estimated life.

Land and buildings (real estate) are accounted according to the revaluation model, recognized at the fair value determined from market-based evidence. Buildings are revaluated as on 31.12.2011 based on the cadastral value as fair value. Accumulated depreciation at the date of the revaluation is eliminated against the gross carrying amount of the asset and the net amount restated to the revalued amount of the asset. Depreciation is calculated based on the revalued amount. The depreciation charge for each period is recognised in the statement of income.

The increase (decrease) in the value of buildings and constructions is reflected in the Statement of comprehensive income under "Gains (losses) from revaluation of properties". Revaluation decreases are charged first against the revaluation surplus in equity related to the specific asset, and any excess against profit or loss.

Depreciation is provided on all fixed assets based on historical cost. Depreciation on fixed assets are computed using the straight-line method over the estimated average useful lives:

Buildings:	20 years
Machinery and equipment:	3 years
Other fixed assets:	5 years

For tax purposes, depreciation on tangible fixed assets is calculated under the double declining balance method over the period established in accordance with prevailing tax legislation.

Investments in associates

Investments in associates are initially recognized at the cost.

Revenue recognition

Sales of goods are recognized when goods are delivered and title has passed.

Dividends

Dividends are recognized as liabilities in the Company financial statements after the Company shareholders made a decision to pay.

LATVIJAS JURAS MEDICINAS CENTRS JSC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIODS ENDED 31 MARCH 2013 AND 31 DECEMBER 2012

Deferred income

Government grants are accounted according to IAS 20. A government grant is recognised only when there is reasonable assurance that the Company will comply with any conditions attached to the grant and the grant will be received.

The grant is recognised as income in the statement of profit or loss and other comprehensive income the period necessary to match them with the related costs, for which they are intended to compensate, on a systematic basis.

Government grants related to assets, including non-monetary grants, are accounted for at fair value, presented as deferred income in the statement of financial position, which are recognised as income from the different exercises on a systematic and rational, over the life of the related assets.

Property revaluation surplus

The revaluation surplus is included in other comprehensive income and accrued amount is reflected in equity under the heading "Investment revaluation reserve". According to IASs 16, p.41, the revaluation surplus included in equity is transferred directly to retained earnings. The surplus transferred is the difference between depreciation based on the revalued carrying amount of the asset and depreciation based on the asset's original cost. Transfers from revaluation surplus to retained earnings are not made through profit or loss.

Taxation

Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in opinion of management, it is more likely than not that some proportion or all deferred tax assets will not be realized.

Deferred tax on revaluation surplus is reflected in the Statement of other comprehensive income.

Risk Management

The Management Board is responsible for setting up risk management guidelines and risk monitoring.

The Company has identified the major risk factors and developed policies and mechanisms to control these factors. The major risks are defined as:

Market risk: a country's economic deterioration, changes in the public and the insurer health care and its financing policy, competition, changes in utility tariffs, etc. can significantly affect the demand for Groups services and its profitability.

Operational risk: The possibility of suffering losses caused by inadequate or failed internal pace of the medical treatment process, actions of staff or systems, or external events impact. Patient dissatisfaction with the quality of medical services, treatment process organization or staff attitudes in the long term can lead to a fall in income and even financial claims.

Credit Risk: The inability of insurance companies and patients to pay for the services in time and in full amount.

Liquidity risk: unable to meet the legally enforceable requirements without major damage and inability to cope with unplanned changes in Groups resources and / or market conditions related to the fact that it does not have sufficient liquid assets.

LATVIJAS JURAS MEDICINAS CENTRS JSC
 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
 FOR THE PERIODS ENDED 31 MARCH 2013 AND 31 DECEMBER 2012

2. TOTAL FIXED ASSETS AND OTHER INTANGIBLE (FIXED) ASSETS

As on 31 March 2013 and 31 December 2012

fixed assets are composed as follows:

EUR	Intangible assets	Land & buildings	Machinery and equipment	Other fixed assets	Fixed assets add-ons (EU funds)	Unfinished building objects	Advance payments for fixed assets	Total
Historical cost								
At 31 December 2011	37 531	3 708 656	3 590 342	480 061	585 610	8 584	156 571	8 567 356
Additions	27 079	69 785	246 968	40 149	321 159	(3 857)	-	701 282
Transfers	-	906 769	-	-	(906 769)	-	-	-
Disposals	-	-	(44 603)	(18 772)	-	-	-	(63 375)
At 31 December 2012	64 610	4 685 210	3 792 708	501 439	-	4 727	156 571	9 205 263
Additions	9 640	-	18 398	9 599	-	(4 727)	-	32 910
Transfers	-	-	-	-	-	-	-	-
Revaluation	-	-	-	-	-	-	-	-
Disposals or change in classification	(865)	(1 686)	(18 554)	(14 217)	-	-	-	(35 323)
At 31 March 2013	73 385	4 683 523	3 792 551	496 820	-	0	156 571	9 202 850
Accumulated depreciation								
At 31 December 2011	36 490	1 943 427	2 326 498	424 306	-	-	-	4 730 720
Charge for the year	6 446	76 905	397 863	40 902	-	-	-	522 116
Charge for the period for revaluated fixed assets	-	163 182	-	-	-	-	-	163 182
Disposals	-	-	(44 603)	(17 659)	-	-	-	(62 262)
At 31 December 2012	42 935	2 183 513	2 679 759	447 549	-	-	-	5 353 756
Charge for the year	3 031	24 290	99 749	10 091	-	-	-	137 161
Charge for the period for revaluated fixed assets	-	40 795	-	-	-	-	-	40 795
Disposals or change in classification	(865)	(1 686)	(18 544)	(14 213)	-	-	-	(35 309)
At 31 March 2013	45 101	2 246 912	2 760 963	443 427	-	-	-	5 496 403
Net book value								
At 31 December 2011	1 042	1 765 229	1 263 845	55 755	585 610	8 584	156 571	3 836 636
At 31 December 2012	21 675	2 501 696	1 112 949	53 890	-	4 727	156 571	3 851 508
At 31 March 2013	28 284	2 436 611	1 031 588	53 393	-	0	156 571	3 706 447

LATVIJAS JURAS MEDICINAS CENTRS JSC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIODS ENDED 31 MARCH 2013 AND 31 DECEMBER 2012

3. INVESTMENT IN ASSOCIATES

	Capital share (%)	Amount of investment	Capital share (%)	Amount of investment
	2013		2012	
	EUR		EUR	
Participating interests in associated enterprises				
Participation in "Neirozu klinika" Ltd.	45,32	<u>192 532</u>	45,32	<u>192 532</u>
Total participating interests in associated enterprises		<u><u>192 532</u></u>		<u><u>192 532</u></u>

4. RAW MATERIALS

	2013	2012
	EUR	EUR
Pharmaceutical	79 076	96 927
Food products	-	-
Advance payments to supplier of goods	277	391
Inventory in warehouse	-	-
Inventory[re-usable]	-	-
Other materials	124	357
Total	<u><u>79 477</u></u>	<u><u>97 676</u></u>

5. TRADE RECEIVABLES

	2013	2012
	EUR	EUR
Riga's health department	159 360	9 933
P.Stradiņa klīniskā universitātes slimnīca	8 416	24 865
Other customers	26 333	22 819
Insurance BTA SE	33 681	29 320
Ergo Latvija AAS	4 654	3 392
Gjensidege Baltic	6 514	4 963
IF Latvija AAS	4 957	2 484
Latvian University	2 086	4 172
SEESAM Latvija	1 942	2 943
Latvian railway JSC	1 722	1 722
Olla M Ltd.	831	1 652
Balva AAS	3 075	1 030
Baltijas apdrošināšanas nams	3 593	1 614
Biogen Idec Ltd.	178	178
Balta AAS	-	680
Compensa Life Vienna Insurance group	2 129	1 384
Ministry of Interior – health and social department	1 299	1 207
Narkologijas centrs	-	-
Bad debt provisions	(3 907)	(3 950)
Total	<u><u>256 863</u></u>	<u><u>110 406</u></u>

LATVIJAS JURAS MEDICINAS CENTRS JSC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIODS ENDED 31 MARCH 2013 AND 31 DECEMBER 2012

6. OTHER RECEIVABLES

	2013	2012
	EUR	EUR
Taxes overpaid (note No.12)	5 114	5 111
VAT for unpaid invoices	598	2 906
Other receivables	6 571	1 484
Total	12 282	9 501

7. DEFERRED EXPENDITURE

	2013	2012
	EUR	EUR
Assurance	2 193	3 960
Total	2 193	3 960

8. CASH FUNDS

	2013	2012
Cash in banks	812 282	1 022 511
Cash on hands	16 225	9 121
Total	828 507	1 031 632

9. SHARE CAPITAL

	2013		2012	
	Number of shares	Share %	Number of shares	Share %
Shareholders:				
Ilze Birka	140 000	17,50%	140 000	17,50%
Martins Birks	140 000	17,50%	140 000	17,50%
Ilze Aizsilniece	91 565	11,45%	91 565	11,45%
Guna Shvarcberga	82 917	10,36%	82 917	10,36%
Janis Birks	68 215	8,53%	67 983	8,50%
Adomas Navickas	41 412	5,18%	39 508	4,94%
Other shareholders (shares less than 5%)	235 891	29,49%	238 027	29,75%
Total	800 000	100,00%	800 000	100,00%
Share equity	1 138 297		1 138 297	

10. DEFERRED INCOME

	2013	2012
	EUR	EUR
ERAF projektu izdevumu atlīdzināšana	596 678	596 678
Total	596 678	596 678

11. ADVANCE PAYMENTS

	2013	2012
	EUR	EUR
VEK advance payment for 2010	4 169	4 169
Other advances	1 614	14 101
Total	5 783	18 270

12. TRADE PAYABLES

	2013	2012
	EUR	EUR
Tradintek	28 089	54 386
Būvprojektu vadība	-	-
Latvijas Gaze	-	-
Latvenergo Rīgas elektrotīkls	-	11 192
Sistēmu Audits SIA	3 443	6 026
Rīgas Ūdens	1 137	978
Academic histologic laboratory	161	152
Amerilat MD	-	-
Lattelekom	-	-
Other suppliers	61 810	17 037
Total	94 639	89 772

LATVIJAS JURAS MEDICINAS CENTRS JSC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIODS ENDED 31 MARCH 2013 AND 31 DECEMBER 2012

13. TAXES AND SOCIAL SECURITY PAYMENTS

	As of 31- 12-12	Calculated	Paid	Returned	As of 31- 3-13
	EUR	EUR	EUR	EUR	EUR
Value added tax	1 285	8 247	(7 903)	-	1 629
Social insurance	76 310	224 891	(225 343)	-	75 858
Personal income tax	43 314	122 775	(125 879)	-	40 210
Corporate income tax	(5 105)	-	-	-	(5 105)
Unemployment duty	115	378	(377)	-	117
Natural resources tax	238	-	(246)	-	(9)
Uzņēmuma vieglo a/m trasp.nodoklis	-	-	-	-	-
Real estate tax	(6)	12 786	(1 316)	-	11 464
Total, including	116 150	369 077	(361 064)	-	124 164
due to the budget	121 261				129 278
overpayment	(5 111)				(5 114)

14. OTHER PAYABLES

	2013 EUR	2012 EUR
Salaries	133 824	141 765
Trade union	864	913
Deposited salary	545	484
Total	135 233	143 162

15. NET SALES

	2013 EUR	2012 EUR
Medical ambulant services	794 266	3 404 850
Medical hospital services	273 070	1 269 673
Insurance payments	85 704	301 448
VS ZDC ambulant services	63 617	228 966
Services - minimum fixed part	3 287	13 144
Residents training	6 258	37 110
Stomatology services	15 632	64 526
Family doctors	9 576	39 557
Other income	608	32 467
Total	1 252 016	5 391 741

16. COST OF GOODS SOLD

	2013 EUR	2012 EUR
Salaries and wages	569 492	1 2 121 882
Fixed assets depreciation	177 957	1 685 298
Medical goods	207 305	1 677 331
Social tax	133 834	1 498 042
VAT - expenses	72 073	1 317 670
Public utilities	75 187	1 232 980
Repair expenses	23 607	1 194 499
Rent of equipment	-	1 -
Household goods	7 927	1 30 945
Security ezpenses	8 748	1 33 867
Current assets write-off	23 776	1 84 796

LATVIJAS JURAS MEDICINAS CENTRS JSC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIODS ENDED 31 MARCH 2013 AND 31 DECEMBER 2012

16. COST OF GOODS SOLD (Continued..)

	2013	2012
	EUR	EUR
Computer maintenance, repair	16 100	25 661
Medical researches	5 525	25 441
Advertising	4 059	17 850
Office expenses	3 746	9 446
Utilities	6 318	21 675
Feeding expenses	7 250	38 349
Insurance expenses	1 320	4 834
Transport expense	2 221	9 508
Employees trainings	1 487	9 606
Allowances to employees	356	1 707
Unemployment duty	377	1 485
Gifts to employees	240	847
Accruals for vacations	(43)	(2 709)
Received discounts	(2 780)	(14 644)
Other operating expenses	27 766	108 769
Total	<u>1 373 848</u>	<u>5 135 134</u>

17. ADMINISTRATIVE EXPENSES

	2013	2012
	EUR	EUR
Salaries and wages	61 471	261 019
Social tax	14 741	61 376
Board remuneration	8 159	33 583
Board chairperson remuneration	12 065	31 117
Communication expenses	2 796	15 181
Council members remuneration	4 781	19 123
Office expenses	2 221	8 174
Presentation expenses	339	2 927
Council chairperson remuneration	2 049	8 196
Audit expenses	2 001	7 114
Board members social tax	2 264	7 137
Chairperson of the Board social tax	1 965	7 496
Bank expenses	1 615	5 807
Council members social tax	1 029	4 135
Other administrative expenses	571	2 730
Chairperson of the Council social tax	494	1 975
Legal services	-	2 234
Total	<u>118 558</u>	<u>479 323</u>

18. OTHER OPERATING INCOME

	2013	2012
	EUR	EUR
Rent income	24 106	72 645
Hotel services – food	5 275	17 554
Utilities for tenants	2 467	14 139
Feeding income	-	-
Laundry income	341	1 225
Solarium income	145	679
Other income	9 767	43 588
Total	<u>42 101</u>	<u>149 830</u>

LATVIJAS JURAS MEDICINAS CENTRS JSC
 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
 FOR THE PERIODS ENDED 31 MARCH 2013 AND 31 DECEMBER 2012

19. OTHER OPERATING EXPENSES

	2013	2012
	EUR	EUR
Real estate tax	12 786	686
Penalties	-	511
Loss from fixed assets disposals	16	582
Currency exchange loss	-	-
Other expenses	295	5 384
Total	<u>13 096</u>	<u>7 163</u>

20. INCOME FROM INVESTMENT IN ASSOCIATE

	2013	2012
	EUR	EUR
Neurology clinic Ltd.	-	186
Total	<u>-</u>	<u>186</u>

21. INTEREST INCOME AND SIMILAR INCOME

	2013	2012
	EUR	EUR
Interest income	3	38
Total	<u>3</u>	<u>38</u>

22. CORPORATE INCOME TAX

	2013	2012
	EUR	EUR
Calculated Corporate income tax	-	-
Deferred Corporate income tax	-	17 188
Total	<u>-</u>	<u>17 188</u>

22. CORPORATE INCOME TAX (CONTINUED ...)

	2013	2012
	EUR	EUR
Profit (loss) before tax	(79 825)	(79 825)
Loss from subsidiary	9 425	9 425
Income from the evaluation of the associate company	10 834	10 834
Theoretically calculated corporate income tax, rate 15%	(8 935)	(8 934)
Permanent differences	7 574	7 574
Calculated corporate income tax	<u>-</u>	<u>-</u>
Deferred tax		
Temporary difference between financial statement	(536 812,54)	(536 813)
Temporary difference of fixed assets revaluation	(498 964,15)	(539 759)
Accruals for vacations	69 252,59	69 253
Total temporary differences	(966 524,10)	(1 007 319)
Tax rate applied	15%	15%
Deferred tax liabilities	(144 979,25)	(151 098)
Recognized deferred tax liabilities	<u>144 979,25</u>	<u>151 097,60</u>

LATVIJAS JURAS MEDICINAS CENTRS JSC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE PERIODS ENDED 31 MARCH 2013 AND 31 DECEMBER 2012

Movement and components of deferred tax

Deferred tax liabilities (asset) at the beginning of the financial year	158 044	158 044
Deferred tax charged to the income statement	24 821	24 821
Changes in deferred tax recognised in properties revaluation reserves	<u>(32 052)</u>	<u>(32 052)</u>
Deferred tax liabilities (asset) at the end of the financial year	<u>150 813</u>	<u>150 813</u>